$1.00
-0.02-1.96%
Last update: Nov 12, 4:36 PM
Spero Therapeutics Inc
SPRONASDAQ
Spero Therapeutics fell 61.7% from $2.66 to $1.02, behind the S&P 500's +11.2%. Its worst day was Jun 17 (−23.8%), and its low came Nov 10 at $1.01.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.13 beat the $-0.25 estimate on $5.4M revenue.
−1.2% · S&P 500 0.0%
EPS of $0.53 beat the $-0.25 estimate on $41.3M revenue.
Story events cover the past 12 months · Times ET
−1.7% · S&P 500 −1.7%
EPS of $-0.13 beat the $-0.18 estimate on $258,000.00 revenue.
+13.1% · S&P 500 +0.8%
Spero Therapeutics closed at its highest level of the year, 12.0% above where the year started.
+6.4% · S&P 500 +0.4%
Spero Therapeutics shares fell 23.8%, while the S&P 500 fell 1.5%.
−23.8%, the year's worst day · S&P 500 −1.5%
Spero Therapeutics shares rose 11.9%, while the S&P 500 fell 0.7%.
+11.9% · S&P 500 −0.7%
Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355)Innovent will receive an upfront payment, and is
−22.0% · S&P 500 +0.4%
EPS of $-0.16 was reported on $0.00 revenue.
+4.2% · S&P 500 +0.7%
Spero Therapeutics shares rose 19.3%, while the S&P 500 fell 0.0%.
+19.3%, the year's best day · S&P 500 0.0%
Where it ended: a close of $1.02 on Nov 11, 2026. Up next: Q3 2026 earnings on Nov 12, 2026 (EPS est. $-0.14).
Nothing in the past 12 months.
All SPRO dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for SPRO and SPY from Benzinga historical bars. Not investment advice.
